NIH Reports Metformin Use in Adults with Diabetes and Its Link to Lower Long COVID Risk
Wednesday, 18 September 2024, 06:48
NIH Study Reveals Metformin’s Protective Role Against Long COVID
A recent study funded by the NIH has discovered a noteworthy correlation between the use of metformin by adults with diabetes and a reduced likelihood of developing long COVID. The research aligns with earlier studies that indicated the potential advantages of metformin in this context.
Key Findings
- Metformin use may lower long COVID risk in diabetic patients.
- Large scale studies reveal promising data.
- Implications for ongoing treatment and management of diabetes.
This investigation emphasizes the vital role of metformin not only in managing blood sugar levels but also in potentially mitigating the risks associated with long COVID.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.